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Sarcoidosis is a multisystem granulomatous disease of
unknown aetiology characterized by increased inflam-
mation, and results from gene–environment interac-
tions. Proteinase-activated receptor-1 mediates the
interplay between coagulation and inflammation. The
rs2227744G > A promoter single nucleotide polymor-
phismhas been linked to inflammation,cardiovascular
disease and chronic obstructive pulmonary disease
exacerbations. Using a case-control study (184 cases
with sarcoidosis and 368 controls), we show that
the rs2227744A allele significantly associates with
protection from sarcoidosis (P = 0.003, OR = 0.68
(0.52–0.88)).
Key words: F2R promoter, proteinase-activated receptor-1,
sarcoidosis, single nucleotide polymorphism.
Abbreviations: CI, confidence interval; COPD, chronic obstruc-
tive pulmonary disease; ELSA, English longitudinal study of
ageing; F2R, factor 2 receptor; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; HLA, human leukocyte antigen;
HWE, Hardy–Weinberg equilibrium; MHC, major histocompatibil-
ity complex; OR, odds ratio; PAR-1, proteinase-activated
receptor-1; SNP, single nucleotide polymorphism.
Sarcoidosis is a multisystem granulomatous
disease of unknown aetiology.1 The manifestations of
the disease are diverse,1 but the lungs are affected in
95% of patients2 with an inflammatory response char-
acterized by the development of non-caseating
granuloma.3 The phenotype varies in severity with a
key distinction being the presence or absence of
persistent disease. Up to 17% of UK sarcoidosis
patients will develop pulmonary fibrosis.4 The disease
tracks in families suggesting genetic predisposition
which has been most closely related to the major his-
tocompatibility complex (MHC) region on chromo-
some 6. This region includes the human leukocyte
antigen (HLA)-class I and class-II genes and a large
number of genes involved in immune and inflamma-
tory responses.5 Moreover, there is evidence of
increased procoagulant activity in sarcoidosis, which
significantly correlates with lung function.6
Activation of proteinase-activated receptor-1
(PAR-1) by coagulation proteinases contributes to
lung inflammation and fibrosis, and we have shown
that PAR-1 knock-out mice are protected when these
conditions are experimentally induced.7,8 The minor
allele of the rs2227744G > A single nucleotide poly-
morphism (SNP) in the promoter of the factor 2
receptor (F2R) gene (chromosome 5q13.3) has been
demonstrated to confer higher promoter activity, and
hence higher PAR-1 expression levels, in vitro.9 The
same SNP has been shown to be associated with pro-
tection from frequent chronic obstructive pulmonary
disease (COPD) exacerbations9 and with inflamma-
tion and cardiovascular disease.10
A UK CaucasianWhite population of 184 sarcoido-
sis subjects recruited fromUniversity College London
Hospital, the Royal FreeHospital and St George’s Hos-
pital was used for this study.11 Sarcoidosis was diag-
nosed according to international guidelines1 and
patients were sub-classified into those with persistent
and non-persistent disease.11 Three hundred sixty-
eight age and gender-matched UK Caucasian White
controls were selected among the National Blood
Service individuals, Whitehall II and English longitu-
dinal study of ageing (ELSA) cohorts12,13 (Table 1).
Individuals with lung disease in these latter cohorts
were excluded for the purpose of this study. All
aspects of the study had ethics committee approval,
and written informed consent was obtained from all
participants.
Genotyping of the Whitehall II and ELSA cohorts
was performed by KBiosciences using the KASPar
assay (LGC, Middlesex, UK), based on Kompetitive
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Allele Specific PCR or KASP technology. For the sar-
coidosis cohort andNational Blood Service samples, a
region containing the rs2227744G > A polymorphism
was PCR amplified and the products sequenced using
the MegaBACE automated sequencing and a
MegaBACE 1000DNA analysis system (GEHealthcare,
Little Chalfont, UK) following the manufacturer
instructions. Samples were analysed using a
MegaBACE 1000 DNA analysis system.
For phenotypic data, categorical data were tested
for differences between cases with persistent and
non-persistent disease by means of a chi-square test,
and continuous data were tested using the 2-tailed
Student t-test. For genotypic data, all procedures were
performed using PLINK v1.07.14 Hardy–Weinberg
equilibrium (HWE) was tested using the exact test
described by Wigginton15 and implemented in the
PLINK software.14 For each analysed group, standard
case-control analyses on allele and genotype fre-
quency data were performed with logistic regression
with correction for age and gender. The analyses were
also repeated assuming a dominant and a recessive
model of inheritance.
The characteristics of the sarcoidosis patients and
healthy controls are reported in Table 1. Lung func-
tion data are not available for the healthy blood
donors. Patients with persistent sarcoidosis have
poorer lung function and a restrictive forced expira-
tory volume in 1 s/forced vital capacity (FEV1/FVC)
ratio of 70% or greater as would be expected.
A large cohort of 8579 UK Caucasian healthy indi-
viduals, who participated in the ELSA or Whitehall II
study, was previously genotyped for this polymor-
phism.9 The minor allele frequency in the controls
selected for this study (0.43) was comparable to that
observed in this population (0.45)9 and to those found
in publicly available database for European cohorts
(HapMap3: 0.43 and ALFRED: The Allele Frequency
Database: 0.42). The genotype distributions in the
ELSA and Whitehall II cohorts were calculated (AA/
AG/GG 0.20/0.50/0.30) and were very similar to those
observed in our control population (0.20/0.46/0.34)
and to those reported in the HapMap3 database
(0.18/0.50/0.32).
No significant deviation fromHWEwas observed in
cases (P-value = 0.62) or controls (P-value = 0.34) or
both (P-value = 0.21). Association analyses showed
that the rs2227744A minor allele is associated with
protection from sarcoidosis but not with persistent
and non-persistent phenotype. Allelic chi-square
analyses of cases and controls showed that the
rs2227744A allele was significantly less frequent in
cases compared with controls, with the additive
model being the most significant (P-value = 0.003,
OR = 0.68 (0.52–0.88)). The association was con-
firmed by genotypic analyses (P-value = 0.01) (Table
2). Comparing the allelic frequencies in the persistent
and non-persistent disease groups, no significant
association was found at the allelic (P-value = 0.57,
OR = 1.2 (0.64–2.27) or genotypic level (P-value =
0.34) (Table 2).
Sarcoidosis is believed to result from gene–
environment interactions, though the nature of the
environmental stimulus remains obscure. Multiple
genome-wide association study and candidate gene
studies have suggested relationships between loci
and the development, phenotype or clinical course of
sarcoidosis most often in relation to the MHC/HLA
genes on chromosome 6.5 The locus 5q13.3 contain-
ing the SNP has not so far been identified as associ-
ated with sarcoidosis. We found that the rare
rs2227744A PAR-1 allele is less common in subjects
with sarcoidosis than in controls, but that this did not
track with the key persistent/non-persistent clinical
phenotype. Since the rs2227744A allele in functional
studies is associated with increased F2R promoter
activity, it is tempting to speculate that an enhanced
PAR-1 signalling response afforded by increased
PAR-1 expressionmay, in part, be responsible for pro-
tection from the development of sarcoidosis. This is
consistent with our finding that the same allele is also
protective towards frequent exacerbations in COPD.9
The rs2227744A allele does not distinguish between
persistent and non-persistent disease, suggesting that
this allele protects from the development of sarcoido-
sis but does not influence the course of the disease.
We therefore speculate that the effect of PAR-1 in sar-
coidosis may be related to influences on the early
inflammatory stage of the disease. However, the lack
of statistical significance for the comparison between
persistent and non-persistent phenotype might
reflect a lack of statistical power, given the small
sample size associated with the sub-group analysis
(power 14.3%). Finally, it is also worth mentioning
Table 1 Clinical characteristics of the sarcoidosis patients and healthy controls
Characteristics
Sarcoidosis (n = 184) Controls (n = 368)
Non-persistent
(n = 97)
Persistent
(n = 71)
P-value (non-persistent
vs persistent) All patients All controls
Age (years) 38.7 (10.8) 40.7 (12.1) 0.27 39.7 (11.4) 40.7 (10.4)
Male 37 (38%) 32 (45%) 0.08 75 (41%) 149 (41%)
FEV1 (L) 2.90 (0.89) 2.33 (0.88) <0.001 2.67 (0.92) NA
FVC (L) 3.62 (1.03) 3.19 (1.10) 0.024 3.44 (1.06) NA
FEV1/FVC 0.80 (0.09) 0.73 (0.12) <0.001 0.77 (0.11) NA
Data are presented as mean (standard deviation) or number (%). FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NA,
not available. Total number of sarcoidosis patients includes 16 unclassified patients.
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that our study did not include a replication cohort so
that our observations require further confirmation.
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